Investor Presentaiton
Continued progress on our key FY19 priorities
Key Priorities
Cipla
1
India: Growth & Therapy
Strengthening
2
US: Launches &
Ramp-up
3
ā 22%
Product
partnerships with
Roche and Eli Lilly
7 approvals in Q1 including
Isoproterenol HCI Inj and
Testosterone Cypionate Inj
US Filings Ramp-up
5 ANDAS filed in Q1
On-track for 20+ ANDA
filings in FY19
4
South Africa: Growth
15% Cipla vs 7%
market growth
First-to-Market
Launches planned in Q2
including first biosimilar Filgrastim
Injection
1 IQVIA (IMS) MAT Jun'18
Investor Presentation: Q1FY19
5
Row: Growth & Biosimilars
6
Trastuzumab
deal signed for key Emerging
Markets (ANZ, Colombia and
Malaysia)
08-08-2018
Quality & Compliance
EIR for Goa & Indore Plants
Received
Continued focus on maintaining
compliance & control at all
manufacturing locations
3View entire presentation